Tutorials: Feb 15, 2011 (Vol. 31, No. 4)

Biosensor-Electrospray Mass Spectrometry

Allowing Simultaneous Detection, Identification, and Quantification of Protein-Ligand Interactions

(Page 1 of 1)

    Figure 1. The on-line SAW-ESI-MS combination using a sam®5 biosensor and a six-port-valve microcolumn interface. (A) sam®5 curve of affinity binding and total dissociation (elution) of the ligand; (B) Interface used for sample concentration and desalting of the ligand; and (C) ESI-MS spectrum of the ligand eluted from the sensor chip.
    Click To Enlarge +

    Figure 1. The on-line SAW-ESI-MS combination using a sam®5 biosensor and a six-port-valve microcolumn interface. (A) sam®5 curve of affinity binding and total dissociation (elution) of the ligand; (B) Interface used for sample concentration and desalting of the ligand; and (C) ESI-MS spectrum of the ligand eluted from the sensor chip.

    Protein-protein interactions are integral to a wide range of biological processes, including hormone, neurotransmitter or drug binding, antigen recognition, and enzyme-substrate interactions. Fundamental to each of these interactions is the recognition by a ligand of a unique binding surface where it binds in a defined way to carry out its function.

    Through an understanding of these specific interactions it may be possible to design or discover analogous ligands with altered binding properties and, therefore, to intervene in the biochemical pathway in a highly specific manner. Thus, it is extremely important to delineate the structural characteristics of the bound species in order to develop a model of the binding interaction.

    Once one or more protein-protein interactions have been identified, it is desirable to investigate the interaction(s) in order to obtain a mechanistic understanding of the proteins at the molecular level; understand the interactions functional significance in vivo; and develop methods for specifically disrupting or perturbing the interaction in vivo.

    A number of affinity-based methods have recently been established for the detection and quantification of biomolecular interactions. Methods widely used for characterization of protein-ligand interactions include immunoaffinity-analysis by ELISA and Western blot, isothermal titration calorimetry, and surface plasmon resonance. Most recently, the SAW (surface acoustic wave) biosensor has become increasingly important for the study of biomacromolecular interactions due to its high detection sensitivity in dilute solutions and ability to use crude biological samples.

    The sam®5 biosensor (SAW Instruments) is a chip-based bioaffinity system for real-time, label-free detection of affinity interactions. Unlike SPR which is an optical method, SAW is based on the conversion of a high-frequency signal into a surface acoustic wave due to the inverse piezoelectric effect. The velocity of the SAW is sensitive to changes in mass loading and viscosity, causing shifts in the signal’s amplitude and/or phase, which enable high-sensitivity detection, unlike most other biosensors that are equipped with a readout unit containing a microfluidic cell. Thus, interactions on the gold-coated chip surface can be observed at near-physiological conditions.

    A newly developed method enables both identification and quantification of bioaffinity interactions of biopolymers and was applied for characterization of interaction between immobilized Substance P or Melittin, with Calmodulin. Melittin and Substance P were manually covalently bound to the five sensor elements of the gold Sensor Chip surface, which was prefunctionalized with a thiol-linker. Affinity binding experiments were started after changing to a physiological pH by the injection of Calmodulin. The interface used for online coupling of sam®5 with ESI-MS includes a six-port switching valve unit and reverse phase C4-microguard-column for desalting and concentration of dissociated ligand sample (Figure 1).

    Figure 2. (A) sam®5 binding curves of Calmodulin obtained using on-line SAW-ESI-MS. (B) Mass spectrometric identification of eluted Calmodulin.
    Click To Enlarge +

    Figure 2. (A) sam®5 binding curves of Calmodulin obtained using on-line SAW-ESI-MS. (B) Mass spectrometric identification of eluted Calmodulin.

    Melittin shows an approximately 2.5 times higher affinity binding to Calmodulin as compared with Substance P to Calmodulin. Determination of kinetic data and dissociation constants was performed by a number of Calmodulin injections with increasing concentration alternating with surface regeneration steps, and provides for both systems KD values in low nanomolar range (Figure 2).

    The new method has shown to be applicable for several systems and enables the direct connection of KD analysis for in vitro biomarkers with quantitation and structural characterization by mass spectrometry. The method has also been further applied to other clinically important systems, e.g., human β-amyloid peptides (Alzheimer disease) and human α-synclein (Parkinson disease).


Related content

GEN News Highlights

Insight & Intelligence™

GEN Articles

Application Notes

Webinars

GEN Podcasts

Video Channel

Events

  • ASMS
    May 20-24, 2012 | Vancouver, BC, CANADA

New Products

Best of the Web

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe

e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.

 

All fields are required

Email
  Confirm Email
  First Name
  Last Name
  Organization
  E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

FDA Performance

How much progress do you think FDA has made in reviewing drugs and bringing them to market faster?

Suggest a Poll